A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma

This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.

Trial Details

NCT ID
NCT07791758
Phase
PHASE1 / PHASE2
Sponsor
Nanjing Leads Biolabs Co.,Ltd
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • LBL-024 for Injection
  • Bevacizumab injection
  • Oxaliplatin injection
  • Capecitabine tablets
  • Fruquintinib Capsules
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guilin, Guangxi, China|25.28022,110.29639
  • Nanning, Guangxi, China|22.81667,108.31667
  • Luoyang, Henan, China|34.67345,112.43684

Key Eligibility Criteria

  • Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the…
  • Age 18-75 years (inclusive of boundaries) at the time of signing informed consent form.
  • The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
  • The expected survival time is at least 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →